Trends in Costs and Risk Factors of 30-Day Readmissions for Transcatheter Aortic Valve Implantation

There has been a rapid dissemination of transcatheter aortic valve implantation (TAVI) since it was first approved in the United States (U.S.) in 2011. As the procedure continues to evolve and improve as a modality for treatment of patients with severe symptomatic aortic stenosis, resource utilization in performing TAVI has attained an important focus.1 The Hospital Readmission Reduction program, established in 2012 by the Centers for Medicare and Medicaid Services, penalizes hospitals with higher than expected risk-standardized 30-day readmissions for medical conditions such as heart failure.

Source: The American Journal of Cardiology - September 25, 2020 Category: Cardiology Authors: Sameer Arora, Michael J Hendrickson, Paula D Strassle, Arman Qamar, Ambarish Pandey, Dhaval Kolte, Kranthi Sitammagari, Matthew A Cavender, Gregg C Fonarow, Deepak L Bhatt, John P Vavalle Source Type: research